Singapore, May 15 -- METiS TechBio, a tech-bio company focused on AI-powered nanodelivery innovation, has successfully listed on the Hong Kong Stock Exchange (HKEX), becoming the world's first publicly listed AI-powered drug delivery company and the first AI-powered large-molecule biopharmaceutical company listed on the Hong Kong market.

With the goal of becoming the "SpaceX of pharmaceuticals," METiS TechBio has, within six years of its founding, become the fastest unicorn in China's AI pharmaceutical sector to reach the IPO milestone.

METiS TechBio's IPO was jointly sponsored by Jefferies, Deutsche Bank Securities Asia and CITIC Securities (Hong Kong). A total of 201,229,000 H shares were offered globally, raising over HKD 2.1 billion...